Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 05 Sep 2017 According to a Lexicon Pharmaceuticals media release, data from this study will be presented at the upcoming European Association for the Study of Diabetes (EASD) 53rd annual meeting.
- 05 Dec 2016 Results published in the Lexicon Pharmaceuticals Media Release.